OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

trialsTrialActive

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

A phase 3 trial of Tisagenlecleucel, Lenalidomide, Rituximab in follicular lymphoma, run by Novartis Pharmaceuticals, active and no longer recruiting.